Division of Gynecologic Oncology, Mayo Clinic, Rochester, United States of America.
Division of Gynecologic Oncology, Mayo Clinic, Rochester, United States of America.
Gynecol Oncol. 2019 May;153(2):238-241. doi: 10.1016/j.ygyno.2019.02.018. Epub 2019 Mar 2.
The FIGO staging consensus agreement from 2012 indicates that bowel mucosal invasion for epithelial ovarian cancer (EOC) should be assigned to stage IV disease. Finding no evidence justifying this recommendation, we examined the impact of recto-sigmoid colonic invasion on survival based on depth of invasion.
Patients having recto-sigmoid resection to achieve complete gross resection for stage IIIC/IV EOC between 2003 and 2011 were included. For this study, mucosal invasion alone was not considered as stage IV. Degree of bowel invasion was defined as: serosal/subserosal vs. muscularis/submucosa/mucosa. Patients with only mesenteric invasion were excluded. Intraperitoneal disease (IP) dissemination patterns were defined as pelvic, lower abdomen, upper abdomen, and miliary disease. Comparisons between groups were evaluated using the log-rank test for progression-free and overall survival (PFS, OS) and the chi-square test for IP dissemination pattern.
Eighty-five patients were included with a mean age of 64.5 years. Most cases were serous (87.1%) and stage IIIC (83.5%). There were 53 (62.4%) patients with serosal/subserosal and 32 (37.6%) with muscularis/submucosa/mucosa invasion. Although not statistically significant, PFS and OS both favored cases with deeper invasion (muscularis/submucosa/mucosa vs. serosal/subserosal invasion: median PFS, 33.5 vs. 18.2 months, p = 0.34; median OS, 82.3 vs. 51.5 months, p = 0.46). When comparing patterns of disease dissemination, we observed that patients with serosal/subserosal invasion (vs. those with deeper invasion) tended to have more upper abdominal or miliary disease (67.9% vs. 48.4%, p = 0.08).
Depth of recto-sigmoid colon wall invasion does not have prognostic significance. Our observations do not support assignment to a higher FIGO stage (IV) based solely on this factor.
2012 年 FIGO 分期共识协议指出,上皮性卵巢癌(EOC)的肠黏膜侵犯应归为 IV 期疾病。我们发现没有证据支持这一建议,因此根据侵犯深度检查直肠乙状结肠侵犯对生存的影响。
纳入 2003 年至 2011 年间接受直肠乙状结肠切除术以实现 IIIC/IV 期 EOC 完全大体切除的患者。在这项研究中,仅黏膜侵犯不被认为是 IV 期。肠壁侵犯程度定义为:浆膜/黏膜下 vs. 肌层/黏膜下/黏膜。排除仅肠系膜侵犯的患者。腹腔内疾病(IP)播散模式定义为盆腔、下腹、上腹和粟粒性疾病。使用对数秩检验比较两组间无进展生存(PFS)和总生存(OS),使用卡方检验比较 IP 播散模式。
纳入 85 例患者,平均年龄为 64.5 岁。大多数病例为浆液性(87.1%)和 IIIC 期(83.5%)。浆膜/黏膜下侵犯 53 例(62.4%),肌层/黏膜下/黏膜侵犯 32 例(37.6%)。虽然没有统计学意义,但 PFS 和 OS 均有利于侵犯更深的病例(肌层/黏膜下/黏膜 vs. 浆膜/黏膜下侵犯:中位 PFS,33.5 与 18.2 个月,p=0.34;中位 OS,82.3 与 51.5 个月,p=0.46)。当比较疾病播散模式时,我们观察到浆膜/黏膜下侵犯的患者(与侵犯更深的患者相比)更倾向于出现上腹或粟粒性疾病(67.9% vs. 48.4%,p=0.08)。
直肠乙状结肠壁侵犯深度没有预后意义。我们的观察结果不支持仅基于这一因素将其分配到更高的 FIGO 分期(IV 期)。